Arbutus Biopharma Hits Day Low of $4.21 Amid Price Pressure

Arbutus Biopharma Corp. experienced a significant decline today, with the stock dropping by 8.47% to reach an intraday low of USD 4.21. This performance stands in contrast to the S&P 500, which saw a decrease of 1.52% on the same day. Over the past week, Arbutus Biopharma has faced a similar trend, with a decline of 8.09%, while the S&P 500 fell by 2.31%. Despite today's downturn, Arbutus Biopharma has shown resilience over the past month, posting a gain of 7.73%, significantly outperforming the S&P 500's decline of 2.34%. Over the past year, the company has achieved a remarkable return of 35.42%, compared to the S&P 500's 19.17%. However, year-to-date performance reflects a decrease of 10.19%, contrasting with the S&P 500's smaller decline of 2.53%. With a market capitalization of USD 821 million, Arbutus Biopharma operates within the Pharmaceuticals & Biotechnology sector and has a notable institutional ownership of 65.39%. This suggests a strong interest from institutional investors, who typically have the resources to analyze company fundamentals effectively.